Pfizer and Moderna must revise their COVID-19 vaccine labels to include more detailed warnings about the risks of heart damage, the U.S. Food and Drug Administration (FDA) said Wednesday.
Letters issued to both companies state that post-marketing analysis shows greater risks than previously indicated for myocarditis, or inflammation of the heart muscle, and pericarditis, which refers to inflammation of the sac-like membrane surrounding the heart.